Andrew C. Orth
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Andrew C. Orth
Krystal Biotech, Inc. reported in an 8-K filed August 7, 2023 that Andrew C. Orth resigned as Chief Commercial Officer, effective August 2, 2023. The proxy statement of Krystal Biotech, Inc. reports total compensation of $2,264,328 for Andrew C. Orth in fiscal 2023, including a base salary of $276,515. Disclosed compensation is on record for 4 fiscal years.
“Andrew Orth, the Company's Chief Commercial Officer, notified the Company that he was resigning from his position and his last day with the Company was August 2, 2023.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Krystal Biotech, Inc. (KRYS)
Proxy statement
Start not stated–2023-08-02
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Krystal Biotech, Inc. (KRYS) | Chief Commercial Officer | $276,515 | $2,264,328 |
| 2022 | Krystal Biotech, Inc. (KRYS) | Chief Commercial Officer | $445,833 | $2,850,169 |
| 2021 | Krystal Biotech, Inc. (KRYS) | Chief Commercial Officer | $283,333 | $9,003,058 |
| 2020 | Krystal Biotech, Inc. (KRYS) | Chief Commercial Officer | — | — |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.